Looking at a New Treatment for Non-Small Cell Lung Cancer

Recruiting · Phase 3 · Non Small Cell Lung Cancer · 29 states

Check if I qualify View on ClinicalTrials.gov

About this trial

This study looks at how well telisotuzumab vedotin works compared to docetaxel in adults with non-small cell lung cancer (NSCLC) that has already been treated. The goal is to find out if the new medicine works better and is safe for patients. Participants will receive either telisotuzumab vedotin every two weeks or docetaxel every three weeks. They will be monitored for any changes in their disease and side effects during the study.

This is a Phase 3 trial, meaning it is looking at how well these treatments work and their safety. It is regulated by the FDA, and about 698 participants are expected to join.

Who can join

Adults aged 18 and older can join. This study is for those with a specific type of lung cancer called c-Met overexpressing NSCLC. Participants should have a life expectancy of at least 12 weeks and have had no more than one previous treatment with chemotherapy. Certain gene mutations and other health conditions might affect eligibility, so the trial team will confirm who can participate.

Condition

Non Small Cell Lung Cancer

Age group

Adult, Older adult

Sex

All sexes

The study team makes the final call on eligibility.

What happens in the study

Participants will be randomly assigned to one of two groups. One group will receive telisotuzumab vedotin every two weeks. The other group will get docetaxel every three weeks. All participants will have regular check-ups to monitor their health and any side effects they may experience.